1. Home
  2. CRTO vs EVO Comparison

CRTO vs EVO Comparison

Compare CRTO & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Criteo S.A.

CRTO

Criteo S.A.

HOLD

Current Price

$19.58

Market Cap

1.1B

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.63

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRTO
EVO
Founded
2005
1993
Country
France
Germany
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
CRTO
EVO
Price
$19.58
$3.63
Analyst Decision
Buy
Strong Buy
Analyst Count
9
1
Target Price
$38.44
$7.00
AVG Volume (30 Days)
662.2K
222.7K
Earning Date
02-04-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
83.79
N/A
EPS
3.00
N/A
Revenue
$1,956,800,000.00
$887,396,457.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.42
$8.52
P/E Ratio
$6.84
N/A
Revenue Growth
0.53
N/A
52 Week Low
$19.00
$2.84
52 Week High
$47.27
$4.80

Technical Indicators

Market Signals
Indicator
CRTO
EVO
Relative Strength Index (RSI) 41.70 60.22
Support Level $20.00 $3.58
Resistance Level $21.55 $3.87
Average True Range (ATR) 0.83 0.08
MACD -0.04 0.04
Stochastic Oscillator 2.84 67.09

Price Performance

Historical Comparison
CRTO
EVO

About CRTO Criteo S.A.

Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: